Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wangbi (Zhongerbi) Tablets Case Registration Study for Knee Osteoarthritis
ChiCTR2100053812Phase 4Recruiting
- Sponsor
- Third Affiliated Hospital, Beijing University of Chinese Medicine
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Wangbi in knee osteoarthritis (OA), sponsored by Third Affiliated Hospital, Beijing University of Chinese Medicine. Primary endpoints: Effectiveness, Overall quality of life (EQ-5D) and 2 more. Started Dec 2018; status: recruiting.
02
Drugs
Wangbi
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2100053812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053812.